Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinically relevant changes in family history of cancer over time.
Ziogas A, Horick NK, Kinney AY, Lowery JT, Domchek SM, Isaacs C, Griffin CA, Moorman PG, Edwards KL, Hill DA, Berg JS, Tomlinson GE, Anton-Culver H, Strong LC, Kasten CH, Finkelstein DM, Plon SE. Ziogas A, et al. Among authors: domchek sm. JAMA. 2011 Jul 13;306(2):172-8. doi: 10.1001/jama.2011.955. JAMA. 2011. PMID: 21750294 Free PMC article.
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL; PROSE Study Group. Rebbeck TR, et al. J Clin Oncol. 2005 Nov 1;23(31):7804-10. doi: 10.1200/JCO.2004.00.8151. Epub 2005 Oct 11. J Clin Oncol. 2005. PMID: 16219936
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR. Friebel TM, et al. Among authors: domchek sm. Clin Breast Cancer. 2007 Dec;7(11):875-82. doi: 10.3816/CBC.2007.n.053. Clin Breast Cancer. 2007. PMID: 18269778
Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.
Vicus D, Rosen B, Lubinski J, Domchek S, Kauff ND, Lynch HT, Isaacs C, Tung N, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Vicus D, et al. Gynecol Oncol. 2009 Oct;115(1):135-137. doi: 10.1016/j.ygyno.2009.06.012. Epub 2009 Jul 3. Gynecol Oncol. 2009. PMID: 19577280 Free PMC article.
Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.
Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F; Kathleen Cuningham Consortium for Research into Familial Breast Cancer; Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, Griffin CA, Sutphen R, Brzosowicz J, Gruber S, Finkelstein DM, Schildkraut JM. Moorman PG, et al. Among authors: domchek sm. Breast Cancer Res Treat. 2010 Nov;124(2):441-51. doi: 10.1007/s10549-010-0842-y. Epub 2010 Mar 23. Breast Cancer Res Treat. 2010. PMID: 20309627 Free PMC article.
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR. Domchek SM, et al. JAMA. 2010 Sep 1;304(9):967-75. doi: 10.1001/jama.2010.1237. JAMA. 2010. PMID: 20810374 Free PMC article.
429 results